Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date.

Moitra S, Bhome AB, Brashier BB.

Drug Des Devel Ther. 2015 Apr 7;9:1989-99. doi: 10.2147/DDDT.S53150. eCollection 2015. Review.

2.

Chronic obstructive pulmonary disease.

Vijayan VK.

Indian J Med Res. 2013 Feb;137(2):251-69. Review.

3.

Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD.

Borel B, Provencher S, Saey D, Maltais F.

Pulm Med. 2013;2013:410748. doi: 10.1155/2013/410748. Epub 2013 Jan 28.

4.

Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Sinden NJ, Stockley RA.

Ther Adv Chronic Dis. 2010 Mar;1(2):43-57. doi: 10.1177/2040622310370631.

5.

Differential effects of formoterol on thrombin- and PDGF-induced proliferation of human pulmonary arterial vascular smooth muscle cells.

Goncharova EA, Khavin IS, Goncharov DA, Krymskaya VP.

Respir Res. 2012 Nov 27;13:109. doi: 10.1186/1465-9921-13-109.

6.

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:73-86. doi: 10.2147/COPD.S29444. Epub 2012 Feb 3.

7.

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.

Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:57-71. doi: 10.2147/COPD.S27320. Epub 2012 Feb 3.

8.

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:43-55. doi: 10.2147/COPD.S27319. Epub 2012 Feb 3. Erratum in: Int J Chron Obstruct Pulmon Dis. 2012;7:765.

9.

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.

Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR.

Respir Res. 2011 Apr 26;12:54. doi: 10.1186/1465-9921-12-54.

10.

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Tashkin DP, Fabbri LM.

Respir Res. 2010 Oct 29;11:149. doi: 10.1186/1465-9921-11-149. Review.

11.

Nebulized formoterol: a review of clinical efficacy and safety in COPD.

Gross NJ, Donohue JF.

Int J Chron Obstruct Pulmon Dis. 2010 Aug 9;5:223-32. Review.

12.

Impact of bronchodilator therapy on exercise tolerance in COPD.

Aguilaniu B.

Int J Chron Obstruct Pulmon Dis. 2010 Apr 7;5:57-71. Review.

13.

Optimising treatment for COPD--new strategies for combination therapy.

Welte T.

Int J Clin Pract. 2009 Aug;63(8):1136-49. doi: 10.1111/j.1742-1241.2009.02139.x. Review.

14.

Role of arformoterol in the management of COPD.

King P.

Int J Chron Obstruct Pulmon Dis. 2008;3(3):385-91. Review.

15.

Formoterol in the management of chronic obstructive pulmonary disease.

Steiropoulos P, Tzouvelekis A, Bouros D.

Int J Chron Obstruct Pulmon Dis. 2008;3(2):205-15. Review.

16.
17.

Optimizing bronchodilator therapy in emphysema.

Diaz PT, Bruns AS, Ezzie ME, Marchetti N, Thomashow BM.

Proc Am Thorac Soc. 2008 May 1;5(4):501-5. doi: 10.1513/pats.200708-131ET. Review.

18.

Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.

Whale CI, Sovani MP, Mortimer KJ, Harrison TW, Tattersfield AE.

Br J Clin Pharmacol. 2008 Jun;65(6):841-7. doi: 10.1111/j.1365-2125.2007.03081.x. Epub 2008 Apr 3.

19.

Budesonide-formoterol (inhalation powder) in the treatment of COPD.

Ceylan E.

Int J Chron Obstruct Pulmon Dis. 2006;1(2):115-22. Review.

20.

Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

Salpeter SR, Buckley NS, Salpeter EE.

J Gen Intern Med. 2006 Oct;21(10):1011-9. Erratum in: J Gen Intern Med. 2006 Oct;21(10):1131.

Items per page

Supplemental Content

Write to the Help Desk